New Publication on Decoding Phenotypic Screening: A Collaborative Effort with Janssen Pharmaceutica and Jagiellonian University

Topic:

Thrilled to share our newest publication!

Leveraging the JUMP-CP consortium’s vast dataset, we described and compared multiple Deep Learning approaches for analyzing HCS data, particularly from U2OS cells and employing the CellPainting protocol.

We show strengths and weaknesses of both supervised and self-supervised learning techniques as well as transferability of such models to other datasets. Our findings demonstrate the potential for broader, cost-effective application in drug discovery, offering strategic insights for HCS data analysis.

This publication was made possible through our collaboration with Janssen Pharmaceutica and Jagiellonian University.

Abstract
Biomedical imaging techniques such as high content screening (HCS) are valuable for drug discovery, but high costs limit their use to pharmaceutical companies. To address this issue, The JUMP-CP consortium released a massive open image dataset of chemical and genetic perturbations, providing a valuable resource for deep learning research. In this work, we aim to utilize the JUMP-CP dataset to develop a universal representation model for HCS data, mainly data generated using U2OS cells and CellPainting protocol, using supervised and self-supervised learning approaches. We propose an evaluation protocol that assesses their performance on mode of action and property prediction tasks using a popular phenotypic screening dataset. Results show that the self-supervised approach that uses data from multiple consortium partners provides representation that is more robust to batch effects whilst simultaneously achieving performance on par with standard approaches. Together with other conclusions, it provides recommendations on the training strategy of a representation model for HCS images.

Read the full article here

You might be also interested in:

Where AI Meets Wet-Lab: A Smarter Path to Biologics Discovery Success
Real-time analytics for Clinical Trials
Data Lakehouses: A Strategic Imperative for the Future of Clinical Studies?
Latest progress and tools for de novo generation of peptides

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!